Condition

Primary Biliary Cirrhosis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions1

Lead sponsors shown3

Clinical trials

3 shown

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordNCT01793168 · 2010-07-01

RECRUITING

Study of Abatacept (Orencia) to Treat Primary Biliary CirrhosisNCT02078882 · 2014-09-01

COMPLETED

Spontaneous Coronary Artery Dissection (SCAD) and AutoimmunityNCT03941184 · 1995-01-01

COMPLETED

Common interventions

abataceptBIOLOGICAL1

Leading sponsors

Christopher Bowlus, MD 1 Mayo Clinic 1 Sanford Health 1

Trial status mix

COMPLETED2

RECRUITING1

Phase mix

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.